Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer

Background Studies suggest that combining radiotherapy (RT) with programmed cell death protein 1 (PD‐1) blockade may elicit a synergistic antitumor response. We aimed to assess whether prior or concurrent RT was associated with improved disease control in patients with metastatic non–small cell lung cancer (NSCLC) treated with nivolumab. Methods We conducted a retrospective study of patients receiving nivolumab as second or subsequent line...